For Healthcare Professionals

An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK)

clipboard-pencil

About the study

This is a Phase 1 trial evaluating the safety and efficacy of crizotinib in patients with tumors except non-small cell lung cancer that are positive for ALK.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

  1. histologically or cytologically proven diagnosis of malignancy other than NSCLC
  2. positive for translocation or inversion event involving the ALK gene locus
  3. positive for ALK amplification events
  4. positive for ALK activating point mutations

EXCLUSION CRITERIA

  1. mutations of amplifications involving the c-Met gene but not the ALK gene
  2. concurrent treatment on another therapeutic clinical trial
  3. prior therapy specifically directed against ALK
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall 1-800-718-1021

Study’s details


Contition

Neoplasms Malignant

Age

15+

Phase

Phase 1

Participants needed

44

Est. Completion Date

Jul 2023

Treatment type

Interventional


Sponsor

Pfizer

ClinicalTrials.gov identifier

NCT01121588

Study number

A8081013

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.